Diagnostic accuracy of optical coherence tomography for patients with Ureteral cancer

Diagnostic accuracy of optical coherence tomography for patients with Ureteral cancer - NOCTURN study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049594

Enrollment

Registered

2022-12-01

Start date

2022-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral tumor, Ureteral cancer

Interventions

Optical coherence tomography for ureteral tumor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients suspected of having cTa to cT3 (computed tomography and/or magnetic resonance imaging) 2) ECOG-Performance Status: 0 to 2 3) Patients who are planning to undergo radical nephroureterectomy or partial ureterectomy for ureteral cancer. 4) Age, 20 to 90 years-old 5) Sufficient bone marrow function and organ functions within 60 days before the registration

Exclusion criteria

Exclusion criteria: 1) Patients who cannot agree with enrollment of the study by his/her own intention 2) Inappropriate for the enrolment by the judgement of the physician because of psychosis or psychiatric symptoms

Design outcomes

Primary

Measure	Time frame
The diagnostic accuracy of optical coherence tomography in distinguishing Ta/Tis/T1 tumors and T2/T3 cancers.	—

Secondary

Measure	Time frame
1) The diagnostic accuracy of optical coherence tomography in determining Ta, Tis, T1, T2, and T3 ureteral cancers. 2) The diagnostic accuracy of optical coherence tomography in distinguishing Ta/Tis/T1/T2 tumors and T3 ureteral cancers. 3) The safety of optical coherence tomography test in patients with ureteral cancer (CTCAE ver 5.0). 4) Factors associated with misdiagnosis of optical coherence tomography in ureteral cancer T category.	—

Measure

Time frame

1) The diagnostic accuracy of optical coherence tomography in determining Ta, Tis, T1, T2, and T3 ureteral cancers. 2) The diagnostic accuracy of optical coherence tomography in distinguishing Ta/Tis/T1/T2 tumors and T3 ureteral cancers. 3) The safety of optical coherence tomography test in patients with ureteral cancer (CTCAE ver 5.0). 4) Factors associated with misdiagnosis of optical coherence tomography in ureteral cancer T category.

—

Countries

Japan

Contacts

Public ContactMakito Miyake

Nara Medical University Urology

makitomiyake@naramae-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026